All In Biotech

Drug Trial Radar · NCT07911787

Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults

A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Clinical Study Evaluating the Efficacy and Safety of HS-10380 in Chinese Adult Patients With Acute Schizophrenia

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 476 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

476

Planned (sponsor's estimate)

Start

Nov 4, 2026

Primary completion

Jan 24, 2029

Study completion Feb 7, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, parallel-group, active- and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of HS-10380 versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate the response rate, improvement in disease severity and symptoms, safety and tolerability.

Conditions

  • SCHIZOPHRENIA 1 (Disorder)

Interventions

  • HS-10380Drug

    Oral;QD;W1:dose titration; W 2-3 dose adjust to optimal level;Week 4-6:stable dose

  • AripiprazoleDrug

    Oral;QD;W1:dose titration; W 2-3 dose adjust to optimal level;Week 4-6:stable dose

  • PlaceboDrug

    Oral;QD;W1:dose titration; W 2-3 dose adjust to optimal level;Week 4-6:stable dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (Day 42)Time frame: Baseline and Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.